The takeaway
Kazia Therapeutics Ltd ADR shows a pronounced seasonal pattern over 10 years of data — strongest in November (+17.5%) and softest in May (−6.1%).
Right now
In July, the stock has risen 50% of years, averaging +9.5%, about +7.3 pts better than the S&P 500.
The full picture
Kazia Therapeutics Ltd ADR's most dependable month has been November, higher in 6 of 10 years; May has been its least reliable, up just 10% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in November (+15.1 pts); it has trailed the market most in December (−14.4 pts).
“vs S&P” is Kazia Therapeutics Ltd ADR’s average for a month minus the S&P 500’s average for that same month — isolating Kazia Therapeutics Ltd ADR’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, November has closed higher 40% of the time versus 60% across the last 10 years — the pattern is weakening.
Figures are the typical (median) November return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
November looks the standout, up in 6 of 10 Novembers — yet the appeal is lumpy, leaning on the occasional blow-out year rather than dependable strength.
The headline flatters a touch — its +17.5% average sits well above the +4.2% a typical year delivers, the work of a few big Novembers. That reliability comes with real swings, mind — even November ranges by 28.8% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: November has cleared the S&P 500 by +15.1 points above the index. Some of that is a strong month market-wide, mind — November rises for about 62% of stocks — so the tendency is real if not unique.
A few other months pull their weight: January and March have also closed higher more often than not. On the other side of the ledger, May has been the soft spot — the weakest of 6 months that average a loss (−6.1%), and the edge isn't year-round — the stock has trailed the S&P 500 in December, October, and May. Its roughest month on record was a −64.6% December in 2024 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, November's last five years slipping below its longer-run record.
Hold it loosely, then: the November tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (November), its worst (May), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (November, +17.5%) has run well ahead of its worst (May, −6.1%) — the heatmap above shows how steady that gap has been year to year.
November has been the strongest, averaging +17.5% and closing higher in 6 of 10 years since 2016.
It's the weakest, averaging −6.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade